STC 15
Alternative Names: STC-15Latest Information Update: 07 Jun 2024
At a glance
- Originator Evotec SE; Storm Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action METTL3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Acute myeloid leukaemia; Haematological malignancies
Most Recent Events
- 03 Jun 2024 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumors released by STORM Therapeutics
- 03 Jun 2024 Storm Therapeutics plans a phase I/II trial for Solid Tumours (Combination therapy) in 2024 (Storm Therapeutics pipeline, March 2023)
- 31 May 2024 Efficacy, pharmacodynamics and adverse events data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)